drugset / Trial / NCT02206165

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

NCT02206165

Phase 2 Unknown 456 enrolled Chong Kun Dang Pharmaceutical
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.

Timeline

Start
2014-03
Primary completion
2015-04
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Candesartan Unknown 8 mg Oral
Subject Candesartan Unknown 16 mg Oral